תוצאות חיפוש

PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models מאת Helen Y. Zou, Luc Friboulet, David P. Kodack, Lars D. Engstrom, Qiuhua Li, Melissa West, Ruth W. Tang, Hui Wang, Konstantinos Tsaparikos, Jinwei Wang, Sergei Timofeevski, Ryohei Katayama, Dac M. Dinh, Hieu Lam, Justine L. Lam, Shinji Yamazaki, Wenyue Hu, Bhushankumar Patel, Divya Bezwada, Rosa L. Frias, Eugene Lifshits, Sidra Mahmood, Justin F. Gainor, Timothy Affolter, Patrick B. Lappin, Hovhannes J. Gukasyan, Nathan Lee, Shibing Deng, Rakesh K. Jain, Ted W. Johnson, Alice T. Shaw, Valeria R. Fantin, Tod Smeal

קבל טקסט מלא קבל טקסט מלא

The use of stained cytologic direct smears for <i>ALK</i> gene rearrangement analysis of lung adenocarcinoma מאת Bryan L. Betz, Catherine A. Dixon, Helmut C. Weigelin, Stewart M. Knoepp, Michael H. Roh

קבל טקסט מלא קבל טקסט מלא

ALK‐positive non–small cell lung cancer: Mechanisms of resistance and emerging treatment options מאת Conor Steuer, Suresh S. Ramalingam

קבל טקסט מלא קבל טקסט מלא

Updated Evidence on the Mechanisms of Resistance to ALK Inhibitors and Strategies to Overcome Such Resistance: Clinical and Preclinical Data מאת Gouji Toyokawa, Takashi Seto

קבל טקסט מלא קבל טקסט מלא

ALK-rearrangements and testing methods in non-small cell lung cancer: a review מאת Rodney E. Shackelford, Moiz Vora, Kim Mayhall, James D. Cotelingam

קבל טקסט מלא קבל טקסט מלא

Diagnostic assays for identification of anaplastic lymphoma kinase‐positive non–small cell lung cancer מאת Andrew Weickhardt, Dara L. Aisner, Wilbur A. Franklin, Marileila Varella‐Garcia, Robert C. Doebele, D. Ross Camidge

קבל טקסט מלא

Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK+ Tumors מאת Amit Dipak Amin, Soumya Sundara Rajan, Winnie S. Liang, Praechompoo Pongtornpipat, Matthew J. Groysman, Edgar O. Tapia, Tara L. Peters, Lori Cuyugan, Jonathan Adkins, Lisa M. Rimsza, Yves A. Lussier, Soham D. Puvvada, Jonathan H. Schatz

קבל טקסט מלא

Native and rearranged ALK copy number and rearranged cell count in non–small cell lung cancer מאת D. Ross Camidge, Margaret C. Skokan, Porntip Kiatsimkul, Barbara A. Helfrich, Xian Lu, Anna E. Barón, Nathan Schulte, DeLee Maxson, Dara L. Aisner, Wilbur A. Franklin, Robert C. Doebele, Marileila Varella‐Garcia

קבל טקסט מלא

Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) מאת Anita Kort, Rolf W. Sparidans, Els Wagenaar, Jos H. Beijnen, Alfred H. Schinkel

קבל טקסט מלא

Crizotinib‐Resistant Mutants of EML4‐ALK Identified Through an Accelerated Mutagenesis Screen מאת Sen Zhang, Frank Wang, Jeffrey Keats, Xiaotian Zhu, Yaoyu Ning, Scott Wardwell, Lauren Moran, Qurish K. Mohemmad, Rana Anjum, Yihan Wang, Narayana I. Narasimhan, David C. Dalgarno, William C. Shakespeare, Juan J. Miret, Tim Clackson, Victor M. Rivera

קבל טקסט מלא קבל טקסט מלא

Intragenic anaplastic lymphoma kinase (<i>ALK</i>) rearrangements: Translocations as a novel mechanism of <i>ALK</i> activation in neuroblastoma tumors מאת Susanne Fransson, Magnus Hansson, Kristina Ruuth, Anna Djos, Ana P. Berbegall, Niloufar Javanmardi, Jonas Abrahamsson, Ruth H. Palmer, Rosa Noguera, Bengt Hallberg, Per Kogner, Tommy Martinsson

קבל טקסט מלא קבל טקסט מלא

Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study) מאת Kengo Takeuchi, Yosuke Togashi, Yuki Kamihara, T. Fukuyama, Hiroshige Yoshioka, Akira Inoue, H Katsuki, Katsuyuki Kiura, Kazuhiko Nakagawa, Takashi Seto, Makoto Maemondo, Toyoaki Hida, M. Harada, Yuichiro Ohe, Naoyuki Nogami, Nobuyuki Yamamoto, Makoto Nishio, Tomohide Tamura

קבל טקסט מלא קבל טקסט מלא

Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation מאת Susan E. Jorge, Sol Schulman, Jason A. Freed, Paul A. VanderLaan, Deepa Rangachari, Susumu Kobayashi, Mark S. Huberman, Daniel B. Costa

קבל טקסט מלא

Identification of Oncogenic Point Mutations and Hyperphosphorylation of Anaplastic Lymphoma Kinase in Lung Cancer מאת Yiwei Wang, Pang‐Hsien Tu, Kuen‐Tyng Lin, Shuchen Lin, Jenq‐Yuh Ko, Yuh‐Shan Jou

קבל טקסט מלא

Evaluation of EML4-ALK Fusion Proteins in Non–Small Cell Lung Cancer Using Small Molecule Inhibitors מאת Yongjun Li, Xiaofen Ye, Jinfeng Liu, Jiping Zha, Lin Pei

קבל טקסט מלא

Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib מאת Justin F. Gainor, Daniel Shao-Weng Tan, Tomasso De Pas, Benjamin Solomon, Aziah Ahmad, Chiara Lazzari, Filippo de Marinis, Gianluca Spitaleri, Katherine R. Schultz, Luc Friboulet, Beow Y. Yeap, Jeffrey A. Engelman, Alice T. Shaw

קבל טקסט מלא

Crizotinib: A comprehensive review מאת Kumar Prabhash, Vanita Noronha, Amit Joshi, Saral Desai, Arvind Sahu

קבל טקסט מלא

Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De... מאת Sai‐Hong Ignatius Ou, Eunice L. Kwak, Christina T. Siwak-Tapp, Joni Dy, Kristin Bergethon, Jeffrey W. Clark, D. Ross Camidge, Benjamin Solomon, Robert G. Maki, Yung‐Jue Bang, Dong‐Wan Kim, James G. Christensen, Weiwei Tan, Keith D. Wilner, Ravi Salgia, A. John Iafrate

קבל טקסט מלא קבל טקסט מלא

Activity of second‐generation ALK inhibitors against crizotinib‐resistant mutants in an NPM‐ALK model compared to EML4‐ALK מאת Diletta Fontana, Monica Ceccon, Carlo Gambacorti‐Passerini, Luca Mologni

קבל טקסט מלא קבל טקסט מלא

Identification of a Novel HIP1-ALK Fusion Variant in Non–Small-Cell Lung Cancer (NSCLC) and Discovery of ALK I1171 (I1171N/S) Mutations in Two ALK-Rearranged NSCLC Patients with Re... מאת Sai‐Hong Ignatius Ou, Samuel J. Klempner, Joel Greenbowe, Michele C. Azada, Alexa B. Schrock, Siraj M. Ali, Jeffrey S. Ross, Philip J. Stephens, Vincent A. Miller

קבל טקסט מלא